

REMARKS

Claims 1-5 and 27-30 are now pending in this application.

Claims 6-26 were canceled. Original claims 1-5 were amended and new claims 27-30 were added to more particularly point out and distinctly claim the invention. The amendments to the claims and the newly added claims are believed to be fully supported within the originally filed application. The amendments to claims 1-5 are supported such as on page 10, paragraph 55. New claims 27-30 which include the pharmaceutically acceptable carrier are supported in the original application such as on pages 14-18 in paragraphs 75-92. Specific information relating to the concentration of the protein within the carrier is supported in the original application on page 6 in paragraph 35. No new matter has been added.

Response to Restriction Requirement

In response to the Restriction Requirement applicants elect Group I containing claims 1-5. The non-elected claims contained within Groups II-IV which include claims 6-26 have been canceled from the application. Applicants reserve the right to file a divisional application directed to the invention encompassed by these claims or other inventions disclosed and described in the application.

Response to Election of Species Requirement

In response to the election of species requirement applicants elect the species directed to SEQ ID NO:18. Applicants point out that claims 1, 2 and 27 are generic and encompass the elected species of SEQ ID NO:18. Applicants request that the generic claims be examined and if filed allowable over the prior art that the non-elected species of SEQ ID NOS: 24 and 30 also be examined and indicated as being allowable.

The above response is believed to be responsive to all of the issues raised by the Examiner. Should the Examiner require further information or consider any of the above not to be completely responsive the Examiner is respectfully requested to contact the undersigned attorney at the indicated telephone number to arrange for an interview to expedite the disposition of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number UCSF-264CON.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 11/Sept/02

By: Karl Bozicevic
Karl Bozicevic
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Direct: (650) 833-7735
Facsimile: (650) 327-3231

F:\DOCUMENT\UCSF\264CON\resp restr reqment.rtf

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend claims 1-5 and add the following new claims 27-30. Please cancel claims 6-26.

1. (Amended) An isolated anti-angiogenic peptide substantially identical to about 10 to about 150 consecutive amino acids selected from the N-terminal end of human placental lactogen, human growth hormone, or growth hormone variant hGH-V, wherein the peptide

- (i) inhibits capillary endothelial cell proliferation and organization;
- (ii) inhibits angiogenesis in chick chorioallantoic membrane; and
- (iv) binds to at least one specific receptor which does not bind to intact full length growth hormone, placental lactogen, or growth hormone variant hGH-V.

2. (Amended) The isolated peptide of claim 1, wherein the peptide is generated by enzymatic cleavage of growth hormone, placental lactogen, or growth hormone variant hGH-V.

3. (Amended) The isolated peptide of claim 1 having the amino acid sequence of SEQ ID NO:18.

4. (Amended) The isolated peptide of claim 1 having the amino acid sequence of SEQ ID NO:24.

5. (Amended) The isolated peptide of claim 1 having the amino acid sequence of SEQ ID NO:30.

Please cancel claims 6-26.

27. (New) The isolated peptide of claim 1, further comprising:
a pharmaceutically acceptable carrier.

28. (New) An isolated peptide having an amino acid sequence of SEQ ID NO:18 present in a pharmaceutically acceptable carrier in a concentration in a range of from about 0.8 to about 1 nM.

29. (New) An isolated peptide having an amino acid sequence of SEQ ID NO:24 present in a pharmaceutically acceptable carrier in a concentration in a range of from about 0.8 to about 1 nM.

30. (New) An isolated peptide having an amino acid sequence of SEQ ID NO:30 present in a pharmaceutically acceptable carrier in a concentration in a range of from about 0.8 to about 1 nM.